RecruitingNCT05463796

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer


Sponsor

Dana-Farber Cancer Institute

Enrollment

5,000 participants

Start Date

Apr 25, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. * The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.


Eligibility

Plain Language Summary

Simplified for easier understanding

This study is building a long-term research registry to monitor, prevent, and catch cancer early in people who are at higher-than-average cancer risk due to genetics, family history, or pre-cancerous conditions. Rather than testing a treatment, this study collects data over time to learn what works best for surveillance and early interception of cancer. **You may be eligible if...** - You carry a gene mutation that raises cancer risk (e.g., BRCA1/2, Lynch syndrome genes, TP53) - You have a strong personal or family history suggestive of hereditary cancer - You have a diagnosed pre-cancerous condition (e.g., Barrett's esophagus, colorectal polyps, MGUS, lobular carcinoma in situ) - You have another condition known to predispose to cancer (e.g., Li-Fraumeni syndrome, Gorlin syndrome) **You may NOT be eligible if...** - You currently have active cancer requiring treatment - You do not have any identifiable elevated cancer risk factor Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSamples

Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues


Locations(1)

Dana Farber Cancer Institute

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05463796


Related Trials